Why is Hester Biosciences Ltd ?
- Poor long term growth as Net Sales has grown by an annual rate of 9.19% and Operating profit at 4.14% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.25 times
- PAT(Latest six months) At Rs 22.81 cr has Grown at 76.14%
- PBT LESS OI(Q) At Rs 25.18 cr has Grown at 135.33%
- NET SALES(Latest six months) At Rs 177.53 cr has Grown at 22.31%
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 40.63%, its profits have risen by 95.3% ; the PEG ratio of the company is 0.4
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
How much should you hold?
- Overall Portfolio exposure to Hester Bios should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Hester Bios for you?
High Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
At Rs 22.81 cr has Grown at 76.14%
At Rs 25.18 cr has Grown at 135.33%
At Rs 177.53 cr has Grown at 22.31%
Highest at 15.11%
Lowest at 0.54 times
Highest at Rs 34.33 cr.
Highest at 34.29%
At Rs 5.10 cr has Grown at 180.22%
Lowest at Rs 6.54 cr
Here's what is working for Hester Bios
PBT less Other Income (Rs Cr)
PAT (Rs Cr)
Debt-Equity Ratio
Net Sales (Rs Cr)
Net Sales (Rs Cr)
Operating Profit (Rs Cr)
Operating Profit to Sales
PBT less Other Income (Rs Cr)
Here's what is not working for Hester Bios
Interest Paid (Rs cr)
Cash and Cash Equivalents






